Similares a OTP Town Hall: Cell Therapy CMC Readiness for Late-Stage INDs

20 vecinos (text_768) · 1.6K views · U.S. Food and Drug Administration · Estados Unidos


★	OTP Town Hall: Cell Therapy CMC Readiness for Late-Stage INDs	U.S. Food and Drug Administration @us_fda	1.6K	Estados Unidos
3	Biologicsx3DCC Conference 2026: Attend India’s First Unified Biopharma Summit	Biotecnika @biotecnika	—	India	86
7	Biologics x 3DCC 2026: Network with Global Scientists on 22nd & 23rd Jan!	Biotecnika @biotecnika	—	India	85
2	July 29, 2026 Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting	U.S. Food and Drug Administration @us_fda	52.3K	Estados Unidos	86
4	Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) Meeting	U.S. Food and Drug Administration @us_fda	27.0K	Estados Unidos	86
11	Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS	HCPLive @hcplivenews	4.3K	Estados Unidos	85
1	OTP Town Hall: Best Practices for Regulatory Interactions with OTP	U.S. Food and Drug Administration @us_fda	644	Estados Unidos	90
14	GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals	U.S. Food and Drug Administration @us_fda	409	Estados Unidos	85
8	Conversatorio: Las actividades biotecnológicas y la industria farmacéutica	Secretaría de Innovación, Ciencia y Tecnología @innovacionarok	313	Argentina	85
9	GDF2026 - Q&A Discussion Panel Six	U.S. Food and Drug Administration @us_fda	292	Estados Unidos	85
10	GDF2026 - Q&A Discussion Panel Four and Day One Closing	U.S. Food and Drug Administration @us_fda	187	Estados Unidos	85
5	GDF2026 - Bioequivalence (BE) Recommendations for Bridging Pre- and Post-Mitigation Formulations	U.S. Food and Drug Administration @us_fda	160	Estados Unidos	86
15	GDF2026 - Office of Generic Drugs (OGD) Keynote	U.S. Food and Drug Administration @us_fda	144	Estados Unidos	85
18	GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote	U.S. Food and Drug Administration @us_fda	101	Estados Unidos	85
12	GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides	U.S. Food and Drug Administration @us_fda	86	Estados Unidos	85
20	GDF2026 - Prioritization Requests: Prioritizing Original and Supplemental ANDAs	U.S. Food and Drug Administration @us_fda	49	Estados Unidos	85
6	Organ on a Chip and Bioprinting: The Next Frontier in Medicine	@61denhayata @61denhayata	45	—	85
19	Immunopharmacology & Gene Therapy \| Chapter 46 – Brenner & Stevens’ Pharmacology (6th)	Last Minute Lecture @lastminutelecture	25	Estados Unidos	85
13	Empleo de nanomedicina en estudios preclínicos y modelos animales	Nanbiosis Icts @nanbiosis	10	España	85
17	Mini Symposium Cell Based Therapies	RCMI Program UPR Medical Sciences Campus @ciartech	6	—	85
16	On-Demand Vaccine Manufacturing: The Cell-Free Frontier	ContentCascade @contentcascade-v1p	4	—	85